SEP 17·SEC EDGARLow
Cesano Alessandra sold $567K of PBYI
Cesano Alessandra sold 62,150 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.12 ($0.57M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PBYI
PUMA BIOTECHNOLOGY, INC.
Price · $PBYIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $PBYI in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $612K 2 txs
WILSON TROY EDWARD1× · $46K
10b5-1 share of filings100%
Top stories · $PBYIMore →
AUG 14·fool.com
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
AUG 7·yahoo.com
Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
PBYI sentiment & insider activity
Recent PBYI coverage spans financial news, earnings and insider activity.
In the last 30 days, PBYI insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($612K). The most active reporter was WILSON TROY EDWARD with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving PBYI
Insider sale reduces insider ownership but is pre‑arranged, likely limited price impact.
Guidance raise and improved demand metrics for NERLYNX increase near-term earnings visibility, while royalty-rate and trade-policy risks cap upside.
Guidance raises near-term earnings visibility while amended alisertib trial dosing and enrollment timing push catalysts into Q3-Q4.
Guidance raise plus improving NERLYNX demand supports a positive near-term earnings outlook, while higher R&D spend and weaker operating cash flow add risk.
The filing is a corporate governance update; the only potentially market-relevant item is that shareholders did not approve extending the CEO’s Auerbach Warrant term.
AlphAI scores every news story that mentions PBYI with an AI model for sentiment and relevance, and aggregates insider trades from PUMA BIOTECHNOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PBYI
Score
Cesano Alessandra sold $567K of PBYI
Cesano Alessandra sold 62,150 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.12 ($0.57M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min read
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
7 min readPuma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
7 min readPUMA BIOTECHNOLOGY, INC. (PBYI): Results of Operations and Financial Condition
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
7 min readPUMA BIOTECHNOLOGY, INC. (PBYI): Submission of Matters to a Vote of Security Holders
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pbyi20260613_8k.htm false 0001401667 0001401667 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report
2 min readPuma Biotechnology (PBYI) Margin Resilience Tests Bearish Earnings Forecasts In FY 2025 Results
Puma Biotechnology closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Despite improving net profit margins, analysts forecast an 11.2% annual decline in earnings over the next three years, contrasting sharply with its strong multi-year growth. The company's heavy reliance on its single product, NERLYNX, and its low P/E ratio compared to peers, reflect investor caution regarding future profitability and revenue forecasts.
5 min read
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
5 min read
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
2 min read
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Puma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
4 min read
Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
3 min read